Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$2.71 USD
+0.03 (1.12%)
Updated May 3, 2024 04:00 PM ET
After-Market: $2.72 +0.01 (0.37%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Arbutus Biopharma Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 18 | 39 | 11 | 7 | 6 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 18 | 39 | 11 | 7 | 6 |
Selling & Adminstrative & Depr. & Amort Expenses | 96 | 104 | 85 | 64 | 150 |
Income After Depreciation & Amortization | -78 | -65 | -74 | -57 | -144 |
Non-Operating Income | 6 | 2 | 0 | -2 | -20 |
Interest Expense | 0 | 2 | 3 | 4 | 2 |
Pretax Income | -73 | -65 | -76 | -64 | -166 |
Income Taxes | 0 | 4 | 0 | 0 | -13 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -73 | -69 | -76 | -64 | -154 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -73 | -69 | -76 | -64 | -154 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -77 | -64 | -72 | -55 | -76 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 2 | 2 | 68 |
Income After Depreciation & Amortization | -78 | -65 | -74 | -57 | -144 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 165.96 | 150.94 | 106.24 | 75.84 | 57.09 |
Diluted EPS Before Non-Recurring Items | -0.44 | -0.46 | -0.83 | -1.00 | -1.62 |
Diluted Net EPS (GAAP) | -0.44 | -0.46 | -0.83 | -1.00 | -2.89 |
Fiscal Year end for Arbutus Biopharma Corporation falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 2.15 | 4.66 | 4.65 | 6.69 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 2.15 | 4.66 | 4.65 | 6.69 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 22.89 | 26.22 | 23.03 | 24.11 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -20.74 | -21.56 | -18.38 | -17.42 |
Non-Operating Income | NA | 1.48 | 1.50 | 1.46 | 1.27 |
Interest Expense | NA | 0.04 | 0.05 | 0.17 | 0.20 |
Pretax Income | NA | -19.31 | -20.10 | -17.09 | -16.34 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -19.31 | -20.10 | -17.09 | -16.34 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -19.31 | -20.10 | -17.09 | -16.34 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 160.93 | 167.51 | 166.06 | 161.64 |
Diluted EPS Before Non-Recurring Items | NA | -0.12 | -0.12 | -0.10 | -0.10 |
Diluted Net EPS (GAAP) | NA | -0.12 | -0.12 | -0.10 | -0.10 |